Skip to content

To keep going please Log in.

or

By submitting my information, I agree to the Privacy Policy and Terms of Service.

To keep going please Log in.

or

By submitting my information, I agree to the Privacy Policy and Terms of Service.

To keep going please Log in.

or

By submitting my information, I agree to the Privacy Policy and Terms of Service.

To keep going please Log in.

or

By submitting my information, I agree to the Privacy Policy and Terms of Service.

APYX Apyx Medical Corporation Common Stock
$3.98 0.00% 0.00
Notify me if price changes either direction
Interactive Brokers Logotype

Buy APYX stocks now with Interactive Brokers – the most advanced investment platform

Contents
  • Performance
  • Key stats
  • Financials
  • US politician trades
Loading

Key Stats

Market cap. 163.3M
Enterprise value 166.5M
Trailing PE -6.1059092030381
Forward PE -10.698924
PEG Ratio 0.094980809825037
Enterprise to EBITDA -18.648
Enterprise to revenue 3.476
Price to book MRQ 25.67742
Price to sales TTM 3.4089997

Financials

Fiscal Year Ends 2024-12-31
Most Recent Quarter (MRQ) 2025-09-30
Revenue (TTM) 47.9M
EBITDA -8929000
Diluted EPS TTM -0.36
Total Cash (MRQ) 25.1M
Current ratio (MRQ) 4.444
Operating Cash Flow (TTM) -8408000

APYX trades by the US politicians

Percentage
0% 0 sells
100% 0 buys
Amount
$0 0 sells
$0 0 buys
In the last 0 months

Recent APYX News

Home

IMPORTANT NOTICE

Finbold is a news and information website. This Site may contain sponsored content, advertisements, and third-party materials, for which Finbold expressly disclaims any liability.

RISK WARNING: Cryptocurrencies are high-risk investments and you should not expect to be protected if something goes wrong. Don’t invest unless you’re prepared to lose all the money you invest. (Click here to learn more about cryptocurrency risks.)

By accessing this Site, you acknowledge that you understand these risks and that Finbold bears no responsibility for any losses, damages, or consequences resulting from your use of the Site or reliance on its content. Click here to learn more.